Physician profile
Kevin Scott Johnson
NPI 1225336993
$2,895.25
in general payments reported to CMS, 2019-2025
25 companies · $551 in 2025
The $551 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $568 · 2022: $435 · 2023: $726 · 2024: $615 · 2025: $551.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,802 · Education: $89.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,801.95 |
| Education | $89.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $920.39 | 2021-2025 | Keytruda, Lynparza, Zerbaxa |
| Janssen Pharmaceuticals, INC | $389.19 | 2021-2024 | Xarelto |
| Abbvie INC. | $212.47 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $154.90 | 2022-2025 | Ultomiris |
| Incyte Corporation | $128.09 | 2023-2024 | Jakafi, Pemazyre, Monjuvi |
| Melinta Therapeutics, LLC | $114.84 | 2021-2025 | Rezzayo, Orbactiv, Kimyrsa |
| Janssen Biotech, INC. | $111.80 | 2023-2025 | Darzalex, Imbruvica, Tecvayli |
| E.R. Squibb & Sons, L.L.C. | $108.33 | 2021-2024 | Krazati |
| Pfizer INC. | $106.91 | 2021-2025 | |
| Astellas Pharma US INC | $105.12 | 2024 | Xospata |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $85.39 | 2021-2025 | Xifaxan |
| Gilead Sciences, INC. | $66.63 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $63.90 | 2021-2023 | Enhertu |
| Amgen INC. | $60.27 | 2023-2024 | Kyprolis, Blincyto, Repatha |
| Exelixis INC. | $52.81 | 2024 | Cabometyx |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $33.27 | 2022 | |
| Inari Medical, INC. | $25.53 | 2022 | |
| Novartis Pharmaceuticals Corporation | $22.25 | 2023 | |
| Eisai INC. | $21.36 | 2023 | |
| Beone Medicines USA, INC. | $19.74 | 2025 | Brukinsa |
| Beigene USA, INC. | $19.73 | 2024 | Brukinsa |
| Urgo Medical North America, LLC | $19.70 | 2024 | Vashe Wound Solution 250 Ml (8.5 Fl Oz) Flip Top Cap |
| Seagen INC. | $18.13 | 2023 | Adcetris |
| Sumitomo Pharma America, INC. | $17.92 | 2025 | Orgovyx |
| Adc Therapeutics America, INC. | $16.58 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.